Bernstein, Barry M.,Menon, Rajeev M.,Khatri, Amit,Mensing, Sven,Dutta, Sandeep,Cohen, Daniel E.,Podsadecki, Thomas J.,Brun, Scott C.,Awni, Walid M.,Dumas, Emily O.,Klein, Cheri E.
申请号：
AU2016202894
公开号：
AU2016202894A1
申请日:
2016.05.05
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
#$%^&*AU2016202894A120160519.pdf#####ABSTRACT OF THE DISCLOSURE The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). 7695876_1 (GHMatters) P99394.AU.10 GLENYSL150iu 9) (~iimui A40 m BMD Com；uAwd 5i >；)Cu.:ntd CC 12 1 Time (weeks) Figure 6(
